A global Phase 1/2 study for CB 4332 for CFI deficient patients
Latest Information Update: 27 Jan 2024
At a glance
- Drugs CB 4332 (Primary)
- Indications Glomerulonephritis; Haemolytic uraemic syndrome; Immunodeficiency disorders; Membranoproliferative glomerulonephritis
- Focus First in man; Therapeutic Use
- Sponsors Catalyst Biosciences; Gyre Therapeutics
- 09 Sep 2021 According to Catalyst Biosciences media release, the company anticipates the submission of an Investigational New Drug (IND) application and initiation of a global clinical trial for CB 4332 in CFI deficiency in 2022.
- 08 Jul 2021 New trial record
- 01 Jul 2021 According to Catalyst Biosciences media release, this trial is planned for 2022.